MedPath
HSA Approval

ZYNLONTA® FOR INJECTION 10MG/VIAL

SIN17098P

ZYNLONTA® FOR INJECTION 10MG/VIAL

ZYNLONTA® FOR INJECTION 10MG/VIAL

September 25, 2024

ORIENT EUROPHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantORIENT EUROPHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS

Medical Information

L01FX22

Manufacturer Information

ORIENT EUROPHARMA PTE LTD

BSP Pharmaceuticals S.p.A.,(Bulk Production &Primary packager)

Active Ingredients

loncastuximab tesirine

10mg/vial

Documents

Package Inserts

ZYNLONTA PI.pdf

Approved: September 25, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ZYNLONTA® FOR INJECTION 10MG/VIAL - HSA Approval | MedPath